Medicines Formulary - Chapter 4.4: CNS stimulants and drugs for attention deficit hyperactivity disorder

Chapters

Drug name	NICE TAs	Comments
Atomoxetine		ESCAs and additional advice in relation to age of patient and CCG
Atomoxetine		ESCAs and additional advice in relation to age of patient and CCG
Dexamfetamine tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	ESCAs and additional advice in relation to age of patient and CCG
Dexamfetamine tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	ESCAs and additional advice in relation to age of patient and CCG
Guanfacine (Intuniv®)		2nd line Atomoxetine, hospitals to manage/support patient. For the treatment of ADHD in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.
Lisdexamfetamine		ESCAs and additional advice in relation to age of patient and CCG
Lisdexamfetamine		ESCAs and additional advice in relation to age of patient and CCG
Methylphenidate M/R tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	Specialist initiation only, ESCA
Methylphenidate tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	ESCAs and additional advice in relation to age of patient and CCG
Methylphenidate tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	ESCAs and additional advice in relation to age of patient and CCG
Modafinil tablets		Specialist initiation only. For treatment of narcolepsy only.
Solriamfetol (Sunosi®)	TA 758 - Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.